Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

K Gordon
R B Warren
A B Gottlieb
A Blauvelt
D Thaçi
C Leonardi
Y Poulin
M Boehnlein
S Kavanagh
C Arendt
K Reich

Keywords

Psoriasis, Biologics, Certolizumab, efficacy

Abstract

Abstract not available.

References

1. Kurd SK. et al. J Am Acad Dermatol 2009;60:218–24;

2. Rachakonda TD. et al. J Am Acad Dermatol 2014;70:512–6;

3. Elmets CA. et al. J Am Acad Dermatol 2019;

4. Menter A. et al. J Am Acad Dermatol 2009;60:643–59;

5. Menter A. et al. J Am Acad Dermatol 2009;61:451–85;

6. Menter A. et al. J Am Acad Dermatol 2019;80:1029–72;

7. Levin EC. et al. J Dermatol Treat 2014;25:78–82;

8. Gottlieb AB. et al. J Am Acad Dermatol 2018;79:302–14; 9. Gordon K. et al. AAD 2019.